Abstract 188P
Background
Soft tissue sarcomas (STS) are a group of rare and heterogeneous tumors with different clinical and biological behaviors. Better prognosis has been associated to an inflamed tumor microenvironment (TME) characterized by the presence of tertiary lymphoid structures (TLS) and B cells. However, the cellular and molecular mechanisms underlying these clinical associations have not been elucidated yet.
Methods
TME composition and TLS quantification were assessed by sequential IHC with αCD3, αCD20, αCD23 and αCD68 antibodies on specimens obtained from patients with primary or locally recurrent STS enrolled and treated at the Careggi Hospital (RESEARCH study). TME transcriptomic profiling was performed using the nCounter Immunology Panel by NanoString. RNA-sequencing and clinical data for 206 STS patients were retrieved from the TCGA SARC project.
Results
IHC of 23 treatment-naïve STS specimens showed higher TLS density and incidence in the group of non-recurrent patients (11/15) compared to patients developing recurrence (2/8; P=0.039). CD8+ T cell, CD20+ B cell and CD23+ follicular dendritic cell densities are higher in the TME of TLS+ STS. CD20 and CD23 (but not CD8) expression is associated to improved recurrence-free survival (RFS) and overall survival (OS) in our cohort. Transcriptomic analysis of 31 treatment-naïve STSs showed that high expression of genes discriminating for germinal center (GC) B cells correlated to the upregulation of Th17-related genes, and decreased expression of M2-like tumor-associated macrophages (TAMs)-related genes. High expression of GC B cell- and Th17 differentiation-related signatures showed associations to longer RFS in our cohort, and to improved OS in the TCGA SARC cohort. Analysis of 5 samples obtained after neoadjuvant radiotherapy (RT) showed reduced expression of IL17A and GC B-related genes while increased TAM-related gene expression, compared to paired biopsies obtained before RT.
Conclusions
Our data identified a prognostic value for Th17-related genes, suggest a potential crosstalk between GC B cells and Th17 cells in coordinating antitumor immune responses, and a potential role for M2-like TAMs (and RT) in inhibiting TLS formation in STS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
172P - HER2 expression across solid tumors and real-world implications for use of fam-trastuzumab deruxtecan-nxki (T-Dxd)
Presenter: Ahmed Ismail
Session: Poster session 08
173P - Unveiling a novel EpCAM-CD24+ circulating cells with unidentified origin associated with breast cancer distant metastasis
Presenter: Evgeniya Grigoryeva
Session: Poster session 08
174P - Prognostic value of the immune and metabolic profile in the response to neoadjuvant treatment with ICIs in triple-negative breast cancer patients (TNBC)
Presenter: Lucía Serrano García
Session: Poster session 08
175P - Utility of artificial intelligence (AI) in Ki67 scoring of a breast cancer (BC) patient population
Presenter: Xavier Pichon
Session: Poster session 08
176P - ERBB2 amplifications across sex, race, and cancer types
Presenter: Marc Machaalani
Session: Poster session 08
177P - HER2 testing in multiple solid tumors: Concordance between 3 scoring algorithms
Presenter: Wentao Yang
Session: Poster session 08
178P - PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent disease
Presenter: Federica Miglietta
Session: Poster session 08
179P - Multimodal deep learning integrating MRI and molecular profiles for predicting outcomes in triple-negative breast cancer
Presenter: Seong Hwan Park
Session: Poster session 08
181P - Molecular characterization and immune microenvironment analysis of MSI-H patients with or without MMR gene mutations
Presenter: Mengxi Ge
Session: Poster session 08